Q1 EPS Forecast for CARGO Therapeutics Lifted by Analyst

CARGO Therapeutics, Inc. (NASDAQ:CRGX - Free Report) - Equities researchers at William Blair upped their Q1 2025 earnings estimates for shares of CARGO Therapeutics in a research note issued on Thursday, January 30th. William Blair analyst S. Corwin now expects that the company will post earnings of ($0.66) per share for the quarter, up from their previous estimate of ($0.95). William Blair has a "Market Perform" rating on the stock. The consensus estimate for CARGO Therapeutics' current full-year earnings is ($3.74) per share. William Blair also issued estimates for CARGO Therapeutics' Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.77) EPS.

CARGO Therapeutics (NASDAQ:CRGX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.26.

A number of other research analysts also recently issued reports on the company. Piper Sandler downgraded CARGO Therapeutics from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $34.00 to $4.00 in a report on Thursday, January 30th. Chardan Capital downgraded shares of CARGO Therapeutics from a "buy" rating to a "neutral" rating in a report on Thursday, January 30th. JPMorgan Chase & Co. cut shares of CARGO Therapeutics from an "overweight" rating to an "underweight" rating in a report on Thursday, January 30th. Truist Financial cut CARGO Therapeutics from a "buy" rating to a "hold" rating and dropped their target price for the company from $32.00 to $7.00 in a research report on Thursday, January 30th. Finally, HC Wainwright cut CARGO Therapeutics from a "buy" rating to a "neutral" rating in a report on Thursday, January 30th. One analyst has rated the stock with a sell rating and six have given a hold rating to the company. Based on data from MarketBeat.com, CARGO Therapeutics presently has a consensus rating of "Hold" and a consensus target price of $15.00.

CARGO Therapeutics Stock Down 0.5 %

Shares of CRGX stock traded down $0.02 on Monday, hitting $3.70. The company had a trading volume of 907,160 shares, compared to its average volume of 1,667,530. The firm has a market cap of $170.31 million, a P/E ratio of -0.87 and a beta of 2.12. CARGO Therapeutics has a twelve month low of $3.00 and a twelve month high of $33.92. The company has a 50-day moving average price of $13.47 and a 200-day moving average price of $16.95.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC raised its holdings in shares of CARGO Therapeutics by 1.1% during the third quarter. FMR LLC now owns 6,954,476 shares of the company's stock valued at $128,310,000 after acquiring an additional 77,508 shares during the last quarter. RTW Investments LP raised its stake in CARGO Therapeutics by 0.5% in the 3rd quarter. RTW Investments LP now owns 4,098,955 shares of the company's stock valued at $75,626,000 after purchasing an additional 20,833 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of CARGO Therapeutics by 1.8% in the third quarter. Janus Henderson Group PLC now owns 2,675,285 shares of the company's stock worth $49,335,000 after buying an additional 46,659 shares in the last quarter. Wellington Management Group LLP boosted its position in CARGO Therapeutics by 4.1% during the third quarter. Wellington Management Group LLP now owns 2,042,723 shares of the company's stock worth $37,688,000 after acquiring an additional 79,782 shares during the last quarter. Finally, State Street Corp lifted its stake in CARGO Therapeutics by 11.7% in the 3rd quarter. State Street Corp now owns 839,861 shares of the company's stock worth $15,495,000 after purchasing an additional 88,000 shares in the last quarter. 93.16% of the stock is owned by hedge funds and other institutional investors.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.